FDA CLEARS WAIVED CBC FOR NEAR-PATIENT TESTING

Sysmex Granted First-Ever FDA Clearance of a CLIA-Waived CBC Analyzer for Hematology

Share on facebook
Share on twitter
Share on linkedin
Share on print
Share on email

CEO SUMMARY: Market clearance of the first-ever CLIA waived analyzer for complete blood count and three-part differential tests could cut time-to-answer from days to mere minutes for one of the top 20 tests by volume performed at core laboratories. Developer Sysmex America, Inc., foresees its analyzer as a complement to central labs. Basic diagnostics would be performed in physician-operated laboratories while larger central labs continue to provide in-depth analysis and repeat testing.

(PDF download) Read Full Report
No part of this article may be reproduced or posted online without permission from THE DARK REPORT. This document contains confidential copyrighted material.

Comments

Leave a Reply